Standout Papers

Hematopoietic cell transplantation (HCT)-specific comorbidity index:... 1997 2026 2006 2016 1.9k
  1. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT (2005)
    Mohamed L. Sorror, Michael B. Maris et al. Blood
  2. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (1997)
    David G. Maloney, Antonio J Grillo-López et al. Blood
  3. Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells (2017)
    Juliane Gust, Kevin A. Hay et al. Cancer Discovery
  4. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy (2017)
    Kevin A. Hay, Laïla‐Aïcha Hanafi et al. Blood
  5. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells (2016)
    Cameron J. Turtle, Laïla‐Aïcha Hanafi et al. Science Translational Medicine
  6. Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody (1982)
    Richard Miller, David G. Maloney et al. New England Journal of Medicine
  7. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015)
    Daniel Sommermeyer, Michael Hudecek et al. Leukemia
  8. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy (2016)
    Rebecca Gardner, David Wu et al. Blood
  9. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment (2000)
    Thomas A. Davis, Antonio J Grillo-López et al. Journal of Clinical Oncology
  10. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib (2017)
    Cameron J. Turtle, Kevin A. Hay et al. Journal of Clinical Oncology
  11. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results (2012)
    Brian G. Till, Michael C. Jensen et al. Blood
  12. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy (2017)
    Joshua A. Hill, Daniel Li et al. Blood
  13. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience (2017)
    Gilles Salles, Martin Barrett et al. Advances in Therapy
  14. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure (2020)
    Jordan Gauthier, Alexandre V. Hirayama et al. Blood

Immediate Impact

16 by Nobel laureates 27 from Science/Nature 112 standout
Sub-graph 1 of 20

Citing Papers

The total mass, number, and distribution of immune cells in the human body
2023 Standout
CAR T-cell therapy in autoimmune diseases
2023 Standout
46 intermediate papers

Works of David G. Maloney being referenced

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
2018
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
2017 Standout
and 35 more

Author Peers

Author Last Decade Papers Cites
David G. Maloney 14619 11152 6961 7903 493 29.4k
Stephen J. Forman 15823 12044 3892 8877 850 35.1k
Jerome Ritz 9935 12732 4476 18842 599 35.8k
Wolfgang Hiddemann 9152 10804 9636 3027 641 26.7k
Richard E. Champlin 14687 26783 3932 12379 1.1k 44.5k
Arnon Nagler 12317 21125 2746 12354 1.1k 38.4k
William G. Wierda 7911 10760 12673 8012 821 30.9k
Bruce D. Cheson 10432 6315 16587 4916 353 29.1k
David C. Linch 6847 8831 6519 3691 355 20.5k
Jacques J. M. van Dongen 4839 10516 4746 9245 502 27.4k
Gerhard Ehninger 6426 13344 1797 4295 677 24.5k

All Works

Loading papers...

Rankless by CCL
2026